Get the Stockscreener App
2.62
1.50%
-0.04
Alpha Tau Medical Ltd stock is traded at $2.62, with a volume of 7,100.
It is down -1.50% in the last 24 hours and down -14.38% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
See More
Previous Close:
$2.66
Open:
$2.69
24h Volume:
7,100
Relative Volume:
0.08
Market Cap:
$183.67M
Revenue:
-
Net Income/Loss:
$-29.64M
P/E Ratio:
-6.093
EPS:
-0.43
Net Cash Flow:
$-39.43M
1W Performance:
-6.76%
1M Performance:
-14.38%
6M Performance:
+11.97%
1Y Performance:
-10.27%
1-Day Range:
$2.61
$2.70
1-Week Range:
$2.59
$2.9081
52-Week Range:
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.62 | 183.67M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges - TipRanks
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress - TipRanks
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.7% – Time to Sell? - Defense World
Alpha Tau Medical Reports 2024 Financial Results and Advances in Cancer Therapy Trials - TipRanks
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Emitter Market to Witness Remarkable Growth with Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd - openPR
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Looking to Meet Alpha Tau's Management? CFO Available at These March Conferences - StockTitan
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts - TipRanks
Alpha Tau Medical Gets Medical Device Single Audit Program Certification -February 24, 2025 at 10:37 am EST - Marketscreener.com
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification - The Manila Times
Can This New Medical Certification Transform Alpha Tau's Cancer Treatment Rollout? - StockTitan
Locally Advanced Pancreatic Cancer Market to Reach New Heights - openPR
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Announces FDA Approval of IDE Supplement to - GlobeNewswire
Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer - Marketscreener.com
Alpha Tau Medical Ltd. Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT®? to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease - Marketscreener.com
Alpha Tau Gains FDA Approval to Expand Pancreatic Cancer Trial - TipRanks
Major Clinical Trial Expansion: Alpha Tau Doubles Down on Revolutionary Pancreatic Cancer Treatment - StockTitan
Alpha Emitter Market Projected To Witness Massive Growth, - openPR
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day - GlobeNewswire
Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials - TipRanks
Alpha Tau shares interim data across multiple clinical trials at R&D Update Day - TipRanks
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials -January 27, 2025 at 09:02 am EST - Marketscreener.com
Alpha Tau's Cancer Therapy Shows Breakthrough Results in Multiple Clinical Trials - StockTitan
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Still a Buy? - Defense World
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Rises By 7.1% - MarketBeat
Takeout news crowns JPM’s winning stocks - BioCentury
DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth - Investing.com
DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth By Investing.com - Investing.com South Africa
US Penny Stocks To Consider In January 2025 - Simply Wall St
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Should You Buy? - Defense World
Alpha Tau to Present Groundbreaking Cancer Therapy Data at ASCO Symposium - TipRanks
Alpha Tau Announces Upcoming Presentation of New Data at - GlobeNewswire
Alpha Tau Medical to Unveil Groundbreaking Cancer Therapy Data at ASCO GI Symposium - StockTitan
Alpha Tau Medical Ltd. Announces Board Changes - Marketscreener.com
Comparing Integra LifeSciences (NASDAQ:IART) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Up 1% – Should You Buy? - Defense World
Alpha Tau Medical Announces Board Leadership Changes Amid Strategic Expansion - TipRanks
Alpha Tau Medical Ltd. Announces Key Shareholder Decisions at Annual Meeting - TipRanks
Alpha Tau Announces Appointment of Maya Netser to its Board - GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor - Quantisnow
Alpha Tau Medical (NASDAQ:DRTS) Trading Up 1%Should You Buy? - MarketBeat
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):